menu
    • menu
    [{"orgOrder":0,"company":"Fortis Therapeutics","sponsor":"FibroGen","pharmaFlowCategory":"D","amount":"$200.0 million","upfrontCash":"Undisclosed","newsHeadline":"FibroGen Enters into Exclusive License for FOR46 with Fortis Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Licensing Agreement","leadProduct":"FOR46","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Fortis Therapeutics","amount2":0.20000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.20000000000000001,"dosageForm":"Infusion","sponsorNew":"Fortis Therapeutics \/ FibroGen","highestDevelopmentStatusID":"7","companyTruncated":"Fortis Therapeutics \/ FibroGen"}]

    Find Clinical Drug Pipeline Developments & Deals by Fortis Therapeutics

    Menu

    Fortis Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Fortis Therapeutics

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed

                            Fortis Therapeutics

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : FOR46

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : FibroGen

                            Deal Size : $200.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            FibroGen Enters into Exclusive License for FOR46 with Fortis Therapeutics

                            Details : The collaboration expands FibroGen’s clinical pipeline with potential first-in-class product candidate, FOR46, a potential first-in-class Phase 1 ADC targeting a novel epitope on CD46, being developed for the treatment of metastatic castration-resistan...

                            Brand Name : FOR46

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            May 08, 2023

                            Lead Product(s) : FOR46

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : FibroGen

                            Deal Size : $200.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth